Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model. 2013

A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
Department of Veterinary Disease Biology, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark; Biopharmaceuticals Research Unit, Novo Nordisk A/S, Maaloev, Bagsvaerd, Denmark.

Prophylaxis in severe haemophilia significantly increases health-related quality of life for patients, but the dosing frequency still constitutes a challenge. Thus, there is a need for new treatment options, utilizing compounds with longer duration of action, while still maintaining potency. The objective of this study was to evaluate the acute and prolonged effects of a new glycoPEGylated recombinant factor VIII (rFVIII) (N8-GP) in a venous bleeding model in haemophilia A mice and to compare the efficacy and potency to turoctocog alfa (rFVIII). Following intravenous administration of turoctocog alfa or N8-GP to normal and FVIII-deficient mice, bleeding time and blood loss from a saphenous vein incision were evaluated in an acute dose-response study and a duration of action study. In the acute setting, N8-GP dose dependently reduced the number and duration of bleeding episodes as well as blood loss compared to FVIII-deficient mice, reaching statistical significance at doses as low as 5-10 U kg(-1) . In the duration of action study, a significantly prolonged and maintained effect of N8-GP was found for up to 48 h after dosing, whereas the effect of rFVIII was no longer present for any end-points 24 h after dosing. Seventy-two hours after dosing, no significant effect of either compound was found. This study shows a prolonged haemostatic effect of N8-GP compared to rFVIII supporting other recent studies that N8-GP may hold a potential to increase the quality of life for patients with haemophilia A by reducing dosing frequency.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011092 Polyethylene Glycols Polymers of ETHYLENE OXIDE and water, and their ethers. They vary in consistency from liquid to solid depending on the molecular weight indicated by a number following the name. They are used as SURFACTANTS, dispersing agents, solvents, ointment and suppository bases, vehicles, and tablet excipients. Some specific groups are NONOXYNOLS, OCTOXYNOLS, and POLOXAMERS. Macrogols,Polyoxyethylenes,Carbowax,Macrogol,Polyethylene Glycol,Polyethylene Oxide,Polyethyleneoxide,Polyglycol,Glycol, Polyethylene,Glycols, Polyethylene,Oxide, Polyethylene,Oxides, Polyethylene,Polyethylene Oxides,Polyethyleneoxides,Polyglycols,Polyoxyethylene
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005260 Female Females
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
March 2013, Blood,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
May 2017, Haemophilia : the official journal of the World Federation of Hemophilia,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
November 2010, Haemophilia : the official journal of the World Federation of Hemophilia,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
June 2018, Journal of thrombosis and haemostasis : JTH,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
May 2011, Journal of thrombosis and haemostasis : JTH,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
August 2017, Thrombosis and haemostasis,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
January 2012, Haemophilia : the official journal of the World Federation of Hemophilia,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
November 2023, Haemophilia : the official journal of the World Federation of Hemophilia,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
January 2017, Thrombosis and haemostasis,
A E Pastoft, and M Ezban, and M Tranholm, and J Lykkesfeldt, and B Lauritzen
May 2019, Haemophilia : the official journal of the World Federation of Hemophilia,
Copied contents to your clipboard!